Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Amgen (AMGN) closed at $258.59 in the latest trading session, marking a -1.01% move from the prior day. This move lagged the S&P 500's daily gain of 0.55%. At the same time, the Dow lost 0.06% ...

Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Despite high debt from the Horizon Therapeutics acquisition, Amgen ...